Eden Biodesign will provide process development for Itero Biopharmaceutical’s biosimilar recombinant follicle stimulating hormone. The product has been licenced by Eden's parent company, Watson Pharmaceuticals.
San Francisco Business Journal
Tuesday 20 July 2010
Eden to develop Itero biosimilar
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment